Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever


Creative Commons License

Ugurlu S. , Hacioglu A., Adibnia Y., Hamuryudan V. , Ozdogan H.

ORPHANET JOURNAL OF RARE DISEASES, cilt.12, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1186/s13023-017-0642-0
  • Dergi Adı: ORPHANET JOURNAL OF RARE DISEASES

Özet

Background: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent may be effective in AA amyloidosis resistant to conventional treatments. We report our data on the effect of TCZ in patients with FMF complicated with AA amyloidosis.